Drug Eluting Stent Market to Reach USD 9.47 Billion by 2030, Says Mordor Intelligence

Mordor Intelligence has published a new report on the Drug Eluting Stent Market offering a comprehensive analysis of trends, growth drivers, and future projections.
Introduction

According to a 2025 report by Mordor Intelligence, the drug eluting stent market size is estimated at USD 6.35 billion in 2025 and is expected to reach USD 9.47 billion by 2030, growing at a CAGR of 8.30% during the forecast period.

The drug eluting stent market [https://www.mordorintelligence.com/industry-reports/drug-eluting-stent-market?utm_source=abnewswire] continues to expand as cardiovascular diseases remain a leading cause of mortality worldwide. These stents are widely used to open blocked coronary arteries and prevent restenosis, which makes them a preferred choice for interventional cardiologists. Growing incidence of coronary artery diseases coupled with increasing adoption of minimally invasive procedures has led to a higher number of percutaneous coronary interventions, driving market growth during the forecast period.

Key Trends in the Drug Eluting Stent Market

Adoption of Biodegradable Polymer-based Stents

There is a growing preference for biodegradable polymer-based drug eluting stents. These stents gradually degrade after releasing the drug, reducing the risks of late stent thrombosis and inflammation associated with durable polymers. This trend is expected to continue as hospitals and interventional cardiologists seek safer treatment options with improved patient outcomes.

Increased Approvals of New Drug Eluting Stents

Regulatory bodies across major regions are approving new drug eluting stent products with enhanced designs and drug delivery systems. The introduction of sirolimus-eluting and everolimus-eluting stents with advanced coatings has improved clinical efficacy, supporting market growth.

Shift Toward Third-Generation Stents

Manufacturers are increasingly focusing on third-generation drug eluting stents that use improved drug coatings, thin strut designs, and better deliverability features. These stents are designed to reduce restenosis rates and improve safety compared to earlier generations.

Growing Use in Emerging Markets

Countries in Asia-Pacific and Latin America are witnessing rising adoption of drug eluting stents due to improving healthcare infrastructure, higher disease prevalence, and increasing awareness about advanced interventional cardiology procedures.

Rising Number of Percutaneous Coronary Interventions (PCI)

The increasing number of PCI procedures globally is driving demand for drug eluting stents as they remain a preferred choice for treating coronary artery blockages. This trend is supported by a higher prevalence of lifestyle diseases such as diabetes and hypertension that contribute to coronary artery disease.

Market Segmentation

By Coating

*
Polymer-based Coating: These stents are coated with a polymer that carries and releases the drug into the artery wall to prevent restenosis. They are widely used due to their effectiveness in reducing the risk of artery re-narrowing after stent placement.

*
Polymer-free Coating: These stents do not use any polymer coating to carry the drug. Instead, the drug is embedded directly onto the stent surface or within a micro-porous structure. This design aims to reduce inflammation and late stent thrombosis risks associated with polymer coatings.

By Drug Type

*
Everolimus: Everolimus is widely used in drug eluting stents due to its effective inhibition of smooth muscle cell proliferation, which helps prevent restenosis. It has a favorable safety profile and is used in several leading stent products globally.

*
Zotarolimus: Zotarolimus is a derivative of sirolimus and is known for its rapid uptake by the arterial wall, reducing the risk of late stent thrombosis. It offers effective prevention against neointimal growth and is used in many second-generation stents.

*
Sirolimus: Sirolimus is one of the earliest drugs used in drug eluting stents, known for its potent immunosuppressive and antiproliferative properties. It effectively reduces restenosis rates by preventing smooth muscle cell growth at the stent site.

*
Paclitaxel: Paclitaxel is an anti-mitotic agent that inhibits cell division, reducing the chances of arterial re-narrowing. Although its use has declined compared to newer drugs like everolimus and zotarolimus, it remains a part of some drug eluting stent systems.

*
Biolimus: Biolimus is a highly lipophilic drug similar to sirolimus, designed to provide enhanced retention in the arterial wall. It is mainly used in biodegradable polymer-coated stents to improve safety and reduce late- adverse events.

*
Others: This segment includes other less commonly used drugs in drug eluting stents. Manufacturers continue to research alternative drugs to improve stent performance and patient outcomes.

By Application

*
Coronary Artery Disease: This segment holds the largest share in the market as drug eluting stents are primarily used for treating coronary artery blockages. They help in restoring normal blood flow and reducing the chances of re-narrowing after angioplasty.

*
Peripheral Artery Disease: Although a smaller segment, drug eluting stents are used in treating peripheral artery disease to open narrowed arteries in the legs or other parts of the body, improving blood circulation and reducing pain during walking or daily activities.

By End-User

*
Hospitals: Hospitals are the primary end-users of drug eluting stents as most percutaneous coronary interventions (PCI) are performed in hospital settings. They have advanced catheterization labs, trained interventional cardiologists, and emergency care facilities required for complex cardiovascular procedures.

*
Cardiac Catheterization Labs: Cardiac catheterization labs, often located within hospitals or as independent specialized centers, perform diagnostic and interventional procedures such as angioplasty and stenting. These labs require drug eluting stents for routine and emergency coronary artery disease treatments, contributing significantly to market demand.

*
Ambulatory Surgical Centers: Ambulatory surgical centers perform outpatient procedures, including some interventional cardiology treatments. The adoption of drug eluting stents in these centers is growing as minimally invasive techniques allow patients to be treated efficiently with shorter recovery times and lower healthcare costs.

By Geography

*
North America: North America holds a significant market share due to a high prevalence of coronary artery diseases, widespread adoption of advanced stent technologies, and the presence of major market players.

*
Europe: Europe follows closely behind North America, with countries investing in healthcare infrastructure and adopting newer drug eluting stent systems for cardiovascular treatments.

*
Asia-Pacific: This region is expected to witness the fastest market growth driven by increasing cases of heart diseases, improving healthcare access, and rising adoption of minimally invasive procedures in countries like China, India, and Japan.

*
Middle East and Africa: Growth in this region is supported by increasing investments in healthcare systems, growing awareness about interventional cardiology procedures, and a rising burden of lifestyle diseases.

*
South America: The market in South America is growing due to gradual improvements in healthcare infrastructure, increasing cardiovascular disease prevalence, and the availability of advanced treatment options.

Key Players in the Drug Eluting Stent Market

*
Abbott Laboratories A global leader best known for its Xience everolimus-eluting stents. Abbott continually renews its portfolio with next-generation stents that focus on thinner struts, improved deliverability, and enhanced safety profiles, helping it maintains a strong market position.

*
Boston Scientific Corporation Maker of the Synergy and Promus stent systems, Boston Scientific focuses on refining drug delivery coatings, reducing strut thickness, and enhancing radiopacity. These improvements have bolstered its share in a highly competitive market.

*
Medtronic PLC Known for its Resolute Onyx zotarolimus-eluting stent, Medtronic emphasizes deliverability and clinical safety. It has sustained market share through rapid product iterations utilizing advanced alloys and coatings.

*
Terumo Corporation A key participant in the global DES market, Terumo is recognized for continuous innovation in strut design, polymer coatings, and inventory support systems. Its efforts help retain customers amid physician preference and price pressures.

Conclusion

The drug eluting stent market is expected to maintain steady growth through 2030, supported by the rising prevalence of cardiovascular diseases and the increasing preference for minimally invasive procedures worldwide. Continuous advancements in stent designs, such as the development of third-generation stents with thinner struts and biodegradable polymers, are improving clinical outcomes and patient safety, strengthening market confidence.

For more information: https://www.mordorintelligence.com/ja/industry-reports/drug-eluting-stent-market?utm_source=abnewswire

Industry Related Reports

Drug Device Combination Products Market: [https://www.mordorintelligence.com/industry-reports/drug-device-combination-products-market?utm_source=abnewswire] The Drug Device Combination Products Market report segments the industry into By Product (Drug Eluting Stents, Transdermal Patches, Infusion Pumps, Drug Eluting Balloons, Inhalers, Others), By Application (Cardiovascular, Diabetes, Cancer Treatment, Respiratory Diseases, Others), By End-User (Hospitals, Ambulatory Surgical Centers, Others), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America).

Implantable Drug Delivery Devices Market : The Implantable Drug Delivery Devices Market report segments the industry into By Product Type (Drug-Eluting Stents, Bioresorbable Stents, and More), By Technology (Diffusion-Controlled Implants, Osmotic Pressure-Driven Implants, and More), By Application (Cardiovascular Disorders, Oncology, and More), By End-User (Hospitals and Surgical Centres, Home-Care Settings, and More), and By Geography. The market and forecasts are provided in terms of value (USD).

For More Information : https://www.mordorintelligence.com/industry-reports/implantable-drug-delivery-devices-market?utm_source=abnewswire

Coronary Stents Market: [https://www.mordorintelligence.com/industry-reports/coronary-stent-market?utm_source=abnewswire] The Coronary Stents Market report segments the industry into By Product Type (Drug Eluting Stent, Bare Metal Coronary Stent, and More), By Biomaterial (Metallic, Polymeric, and More), By Mode of Delivery (Balloon-Expandable Stent, Self-Expanding Stent), By End-User (Hospitals, Ambulatory Surgical Centers, and More), and By Geography (North America, Europe, Asia-Pacific, and More). The market forecasts are provided in terms of value (USD).

About Mordor Intelligence: Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals. With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

For any inquiries or to access the full report, please contact:media@mordorintelligence.com https://www.mordorintelligence.com/

Media Contact
Company Name: Mordor Intelligence Private Limited
Contact Person: Jignesh Thakkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=drug-eluting-stent-market-to-reach-usd-947-billion-by-2030-says-mordor-intelligence]
Phone: +1 617-765-2493
Address:5th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli
City: Hyderabad
State: Telangana 500008
Country: India
Website: https://www.mordorintelligence.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.